Showing results (141-150 of 234) with videos related to

Sort By:
Pageof 24
American Journal of Hematology|August 19, 2015
Clinical features of pulmonary arterial hypertension in patients receiving dasatinibNeil P Shah, Nicola Wallis, Harrison W Farber, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 17, 2017
Two threshold levels of vitamin D and the prevalence of comorbidities in outpatients of a tertiary hospitalI N Furuie, M J J Mauro, S Petruzziello, et al.
Cerebral Cortex (New York, N.Y. : 1991)|June 28, 2012
Contributions of low and high spatial frequency processing to impaired object recognition circuitry in schizophreniaDaniel J Calderone, Matthew J Hoptman, Antígona Martínez, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 3, 2016
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid LeukemiaHanna J Khoury, Stuart L Goldberg, Michael J Mauro, et al.
Nucleic Acids Research|May 23, 2019
RETRACTED: A 5' fragment of Xist can sequester RNA produced from adjacent genes on chromatinDavid M Lee, Jackson B Trotman, Rachel E Cherney, et al.
Cell|November 27, 2012
Site-specific silencing of regulatory elements as a mechanism of X inactivationJ Mauro Calabrese, Wei Sun, Lingyun Song, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Therapeutic potential of Relaxin-2 in Heart Failure with preserved Ejection Fraction (HFpEF)Joshua B Palma, Bethann Gabris-Weber, Brenda McMahon, et al.
Cell|April 7, 2015
Systematic discovery of Xist RNA binding proteinsCi Chu, Qiangfeng Cliff Zhang, Simão Teixeira da Rocha, et al.
Leukemia|March 6, 2013
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysisF J Giles, M J Mauro, F Hong, et al.
Leukemia & Lymphoma|November 13, 2019
Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysisDouglas Tremblay, Amber King, Lihua Li, et al.
Pageof 24